The findings expand a body of evidence doctors are using to design treatment plans that aim to reduce side effects and costs. Newer therapies and tests are extending patients’ lives and moving cancer treatment away from a blunt, one-size-fits-all approach. Doctors are getting better at determining who needs the most aggressive care and who can get away with less treatment and lesscollateral damage.
“It’s time to look at less toxic approaches," said Dr. Julie Gralow, chief medical officer and executive vice president of the American Society of Clinical Oncology.
In early-stage pancreatic cancer, patients who had laparoscopic or robot-assisted surgery had similar outcomes to patients who underwent more invasive open surgery, one study presented Monday at the conference showed. Another found a simpler hysterectomy that removed just the uterus and cervix can be safe for some low-risk cervical cancer patients, instead of more complex and expensive radical hysterectomy.
Women who got the simpler surgery had fewer bladder problems and reported better body image, pain levels and more sexual activity. Cancer patients have started demanding more emphasis on quality of life, as some cancers have become more curable and people live longer after treatment, said Dr. Marie Plante, a gynecologic-oncologist at CHU de Quebec in Canada and the cervical-cancer trial’s lead investigator.
“How can I provide top of the line treatment while reducing side effects without jeopardizing the outcome?" Plante said. “It’s that fine line."
هذه القصة مأخوذة من طبعة June 06, 2023 من Mint Mumbai.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة June 06, 2023 من Mint Mumbai.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
Green steel may get a push with output, purchase mandates
The Centre is working on green steel mandates for the local steel industry, supported by government procurement and financial incentives, as the world's second-largest maker of the alloy seeks to prepare the sector for the future.
RBI action on personal loans, KYC takes toll on off-roll work
The Reserve Bank of India's (RBI) push for stricter compliance with know-your-customer (KYC) norms, and its crackdown on the surge in personal loans have had an unlikely fallout: a dip in demand for off-roll workers.
Investors are betting on a market melt-up
A roaring market rally since the U.S. presidential election has driven up the price of everything from shares of technology and manufacturing giants to cryptocurrencies.
India in economic sweet spot, inflation to moderate: Moody's
India's economy is in a sweet spot and its inflation is expected to moderate despite a temporary spurt, Moody's said, projecting optimism about the country's growth prospects despite recent underwhelming data.
Incentive engine to drive modern ships
Subsidies for green, high-tech ships under ₹18,000 cr policy
Cement firms wage war on costs as competition soars
India's cement makers who once flexed their pricing muscles are caught in a bruising price war, eroding margins at a time of rising demand.
Saudi Arabia doesn’t have enough money for its futuristic city
The giant futuristic planned city of Neom is proving a headache for Saudi Arabia. Costs are up, schedules are delayed, and in recent days the world’s largest construction project replaced its chief executive of six years.
EV adoption is a marathon, not a sprint: Audi India
The slowdown in electric vehicle (EV) sales is temporary, and the industry will grow over time, Audi India head Balbir Singh Dhillon said, pointing to the need for extensive charging networks and supportive government policies.
India's trade gap with China soars in Apr-Oct
The country's green transition increases reliance on Chinese imports
14 nations eye India's generic drug model
Countries will specify their requirements, with HLL and MEA coordinating with them for the pharma exports